Skip to search formSkip to main contentSkip to account menu

3 ML insulin degludec 200 UNT/ML Pen Injector [Tresiba]

Known as: INSULIN DEGLUDEC 200 U in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Tresiba], 3 ML Tresiba 200 UNT/ML Pen Injector, Tresiba 200 UNT/ML per 3 ML Pen Injector 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (1)

3 ML insulin degludec 200 UNT/ML Pen Injector
GlycerinHydrochloric AcidPen InjectorSodium Hydroxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Insulin allergy brought out 8 years after starting insulin therapy in a subject with type 1 diabetes mellitus
Dear Editor Diabetes mellitus is increasingly common, and recombinant human insulin is essential in the management of patients… 
2019
2019
[Basal insulin degludec (Tresiba®)].
Insulin degludec (Tresiba®) is characterized by an original mode of prolonged and continuous insulin release after its… 
2017
2017
Formulări moderne cu analogi de insulină
The objective in diabetes’ treatment is to bring the blood sugar levels at the control target, in order to reduce the incidence… 
Review
2017
Review
2017
Clinical Impact of Newer Insulins for the Management of Type 2 Diabetes
Achieving good glycaemic control while avoiding hypoglycaemia, in order to delay or prevent the long term complications in… 
2016
2016
Stoffwechseleinstellung nach erzwungener Therapieumstellung durch Marktrücknahme von Insulin degludec (Tresiba®) bei Patienten mit Diabetes mellitus
2015
2015
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
Aim : The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in… 
Review
2013
Review
2013
Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
Insulin degludec (Tresiba®) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting… 
2013
2013
Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus
Insulin degludec (Tresiba®) is an ultra-long-acting insulin analogue that is also available as a coformulation (Ryzodeg®) with… 
2013
2013
Degludec – une nouvelle insuline retard
L’insuline dégludec (Tresiba®) est une insuline basale donnant après injection sous-cutanée des multi-hexamères solubles, qui… 
2013
2013
Degludec – Ein neues langwirkendes Insulin
Degludec (Tresiba®) ist ein Basalinsulin, das nach subkutaner Injektion lösliche Multi-Hexamere bildet. Diese formen ein Depot… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)